 |
Quotes delayed 20 minutes
|
Strong Buy (4.00 out of 4)
95th percentile
|
|
|
 Preferred Stock Offerings
By Preferred Stock Channel Staff, updated Saturday, July 4, 10:43 PM
Slide #365. Dynavax Technologies Corporation — Preferred Stock Offering
| Company: |
Dynavax Technologies Corporation (NASDAQ:DVAX) |
| Date announced: |
10/24/2013 |
| Shares Offered: |
43,430 |
| Date of Pricing: |
10/25/2013 |
| Price Per Share: |
$1,075.00 |
| Preferred Stock Offering Details: |
Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that it intends to concurrently offer to sell, subject to market and other conditions: (i) shares of its common stock in an underwritten public offering, and (ii) shares of its Series B Convertible Preferred Stock ("Series B") in a separate underwritten public offering. The Series B is non-voting and convertible into shares of Dynavax common stock, provided that conversion will be prohibited if, as a result, the holder and its affiliates would own more than 9.98% of the total number of shares of Dynavax common stock then outstanding. Dynavax anticipates using the net proceeds from the offerings primarily to fund development activities predominantly associated with conducting an additional Phase 3 study of HEPLISAV and seeking regulatory approval to commercialize the vaccine in the United States and Europe, and for other general corporate purposes, including working capital. |
Dynavax Technologies is a biopharmaceutical company focused on utilizing the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Co.'s commercial product, HEPLISAV-B® (Hepatitis B Vaccine (Recombinant), Adjuvanted), is approved for prevention of infection caused by various known subtypes of hepatitis B virus in adults age 18 years and older. Co.'s development efforts are focused on stimulating the innate immune response to treat cancer in combination with other immunomodulatory agents. Co.'s pipeline of product candidates includes: SD-101, which is its cancer immunotherapy candidate; and DV281, which is an investigational TLR9 agonist.
 Open the DVAX Page at Preferred Stock Channel »
| Name: |
Dynavax Technologies Corp |
| Website: |
www.dynavax.com |
| Sector: |
Drugs & Pharmaceuticals |
| Number of ETFs Holding DVAX: |
19 (see which ones) |
| Total Market Value Held by ETFs: |
$90,484,237 |
| Total Market Capitalization: |
$766,000,000 |
| % of Market Cap. Held by ETFs: |
11.81% |
|
Open the DVAX Page at Preferred Stock Channel (in a new window) »
|
|
